



Benjamin Misselwitz

Kontakt

Benjamin Misselwitz

Publikationen (15)

Woelfel S, Dütschler J, Junker D, König M, Graf N, Krieger-Grübel C, Truniger S, Oikonomou V, Leinenkugel G, Koller S, Metzger-Peter K, Wyss J, Krupka N, Frei N, STAR SIGN Study Investigators, Albrich W, Friedrich M, Niess J, Schneiderhan-Marra N, Dulovic A, Misselwitz B, Korte W, Bürgi J, Brand S. XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease. *Aliment Pharmacol Ther* 2024

Woelfel S, Dütschler J, König M, Dulovic A, Graf N, Junker D, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Koller S, Wyss J, Krupka N, Oberholzer M, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Albrich W, Friedrich M, Schneiderhan-Marra N, Misselwitz B, Korte W, Bürgi J, Brand S. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2023; 58:678–691.

Woelfel S, Dütschler J, König M, Graf N, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Wyss J, Krupka N, Albrich W, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Friedrich M, Misselwitz B, Korte W, Bürgi J, Brand S. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. *Aliment Pharmacol Ther* 2022; 57:103–116.

Perrig K, Krupka N, Jordi S, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka S, Juillerat P, Burri E, Zimmermann D, Maillard M, Sulz M, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. *Therap Adv Gastroenterol* 2022; 15:17562848221074188.

Yoganathan P, Rossel J, Jordi S, Franc Y, Biedermann L, Misselwitz B, Hausmann M, Rogler G, Scharl M, Frey-Wagner I, Swiss IBD Cohort Study Group. Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. *BMC Gastroenterol* 2021; 21:310.

Ruiz F, Wyss A, Rossel J, Sulz M, Brand S, Moncsek A, Mertens J, Roth R, Clottu A, Burri E, Juillerat P, Biedermann L, Greuter T, Rogler G, Pot C, Misselwitz B, Swiss IBD Cohort Study Group. A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease. *Br J Pharmacol* 2021; 178:3157–3175.

Misselwitz B, Rickenbacher A, Brand S. [Symptoms, diagnostic and therapy of perianal disease in patients with inflammatory bowel diseases]. *Ther Umsch* 2021; 78:547–558.

Schreiner P, Misselwitz B, von Känel R, Rogler G, Juillerat P, Pittet V, Vavricka S, Scharl M, Greuter T, Baumann C, Valko P, Biedermann L, Rossel J, Swiss IBD Cohort Study Group. Fatigue in inflammatory bowel disease and its impact on daily activities. *Aliment Pharmacol Ther* 2020; 53:138–149.

Misselwitz B, Juillerat P, Sulz M, Siegmund B, Brand S, Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More. *Digestion* 2020; 101 Suppl 1:69–82.

Tcymbarevich I, Misselwitz B, de Vallière C, Rogler G, Ruiz P, Seuwen K, Scharl M, Wagner C, Kullak-Ublick G, Lang S, Cosin-Roger J, Spalinger M, Obialo N, Rossel J, Eloranta J, Swiss IBD Cohort Study Group. The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation. *BMC Gastroenterol* 2019; 19:2.

Kadelka C, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Kouyos R, Günthard H, Trkola A, Cavassini M, Misselwitz B, Liechti T, Ebner H, Schanz M, Rusert P, Friedrich N, Stiegeler E, Braun D, Huber M, Scherrer A, Weber J, Uhr T, Kuster H, Swiss HIV Cohort Study. Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. *J Exp Med* 2018; 215:1589-1608.

Vavricka S, Biedermann L, Michetti P, Straumann A, Misselwitz B, Scharl M, Manser C, Greuter T, Zeitz J, Frei P, Borovicka J, Seibold F, Schoepfer A, Rogler G, Spasojevic M. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey. *Dig Dis* 2017; 35:423-432.

Vavricka S, Misselwitz B, Scharl M, Heinrich H, Manser C, Safroneeva E, Raja Ali R, Rogler G, Schoepfer A, Greuter T, Zeitz J, Biedermann L, Juillerat P, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. *Inflamm Bowel Dis* 2017

Zeitz J, Rogler G, Fried M, Sulz M, Vavricka S, Scharl S, Misselwitz B, Frei P, Biedermann L, Labenz C, Fournier N, Scharl M. Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. *Inflamm Intest Dis* 2017; 1:172-181.

Sulz M, Kröger A, Prakash M, Manser C, Heinrich H, Misselwitz B. Meta-Analysis of the Effect of Bowel Preparation on Adenoma Detection: Early Adenomas Affected Stronger than Advanced Adenomas. *PloS one* 2016; 11:e0154149.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch